clopidogrel has been researched along with prasugrel in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballard, TE; Henderson, JL; Kalgutkar, AS; Obach, RS; Orr, ST; Ripp, SL; Scott, DO; Sun, H | 1 |
| Gong, Y; Jiao, B; Lv, F; Qi, X; Shan, J; Sun, H; Yuan, F; Zhang, B; Zheng, W; Zhu, Y | 1 |
| Chen, XQ; Crain, E; Hua, J; Huang, CS; Lai, A; Lam, PY; Price, LA; Qiao, JX; Rehfuss, R; Seiffert, DA; Shen, H; Wang, TC; Wang, Y; Watson, C; Wexler, RR; Wong, P; Yang, W | 1 |
| Badorc, A; Barré, G; Besse, A; Boldron, C; Bonnet-Lignon, S; Bono, F; Bordes, MF; Briot, C; Delesque, N; Dol, F; Fossey, V; Gau, B; Hérault, JP; Herbert, JM; Lassalle, G; Meneyrol, J; Millet, L; Nazare, M; Pflieger, AM; Rousseaux, T; Savi, P; Tissandié, S; Yvon, X; Zech, G | 1 |
| Chen, B; Danon, JJ; Kassiou, M; Ma, BB; Montgomery, AP | 1 |
2 review(s) available for clopidogrel and prasugrel
| Article | Year |
|---|---|
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
Topics: Animals; Apoproteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Drug Interactions; Heme; Humans; Models, Biological; Pharmacokinetics; Structure-Activity Relationship; Time Factors | 2012 |
Strategies for targeting the P2Y
Topics: Central Nervous System; Ligands; Microglia; Platelet Aggregation; Receptors, Purinergic P2Y12; Signal Transduction | 2022 |
3 other study(ies) available for clopidogrel and prasugrel
| Article | Year |
|---|---|
Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.
Topics: Administration, Oral; Animals; Biological Availability; Clopidogrel; Drug Resistance; Female; In Vitro Techniques; Male; Mice; Microsomes, Liver; Phenylacetates; Platelet Aggregation Inhibitors; Prodrugs; Rats; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Ticlopidine | 2012 |
Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.
Topics: Animals; Blood Coagulation; Dose-Response Relationship, Drug; Drug Discovery; Humans; Indoles; Mice; Microsomes, Liver; Molecular Structure; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rabbits; Rats; Receptors, Purinergic P2Y1; Structure-Activity Relationship; Thrombosis | 2014 |
N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Administration, Oral; Animals; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Humans; Indoles; Injections, Intravenous; Male; Models, Chemical; Molecular Structure; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridazines; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2Y12; Thrombosis | 2014 |